US EPA

4533092 

Journal Article 

Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment 

Goodrich, DW 

2017 

Active surveillance (AS) is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRB/HRPO approval has been obtained for construction and use of new TMAs (PI Mohler and Goodrich). The TMAs from PCaP have been obtained (PI Mohler and Goodrich). Pathology analysis of 1146 patient specimens is complete and construction of TMAs is complete (PI Mohler). Immunostaining of all TMAs is complete (PI Goodrich). IRB/HRPO approval for active surveillance specimens has been obtained (PI Mohler, Goodrich). Enrollment of prostate cancer patients on active surveillance is ongoing (PI Mohler). Immunostaining of prostate cancer biopsy specimen of patients who qualified for active surveillance is complete (PI Goodrich). ELISA assay development for measuring pThoc1 and pThoc1 autoantibodies is complete (PI Goodrich). IRB/HRPO approval for serum samples has been obtained (PI Mohler, Goodrich). Analysis of serum samples from prostate cancer patients of PCaP cohort is complete (PI Goodrich). Analysis of serum samples from prostate cancer patients and corresponding normal subjects of RPCI cohort has been initiated (PI Goodrich). Year 4 of the grant will finish data acquisition and data analysis. Over treatment complicates the clinical management of prostate cancer. Improving the ability to distinguish aggressive from indolent disease is recognized as an unmet need by the 2013 PCRP Overarching Challenges.